Skip to main content
APhA 2024 Annual Meeting and Exposition Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
View Session ViewAttendees 11

BCGP

Advanced Clinical

Medication Management

Virtual

mAb Update in Alzheimer’s Disease 

Monday, March 25, 2024
11:00 AM – 12:00 PM East Coast USA Time
Location: Orange County Convention Center, W311GH
CE: 1.0

ACPE Number: 0202-0000-24-127-L01-P

Number of Hours: 1

Activity Type: Application

Disclosure(s):
Christine Lam, PharmD, BCPS, BCACP, CDCES, BCGP: No financial relationships to disclose
Aducanumab, lecanumab, donanemab, solanezumab, oh my!  Anti-amyloid monoclonal antibodies (MABs) are exploding as new options to delay the progression of Alzheimer’s Disease.  Attend this session to review the evidence related to anti-amyloid MABs, discuss safety considerations and better understand this class's coverage requirements.

Learning Objectives:

  • Interpret evidence related to efficacy of anti-amyloid monoclonal antibodies approved or in the late-stage pipeline for people with Alzheimer’s Disease
  • Compare and contrast evidence related to safety of anti-amyloid monoclonal antibodies approved or in the late-stage pipeline for people with Alzheimer’s Disease. 
  • Explain requirements for coverage of anti-amyloid monoclonal antibodies and monitoring
  • Discuss the role of anti-amyloid monoclonal antibody therapy in treating Alzheimer’s Disease